

BCOP Webinar Series: A Review of Oral Hypomethylating Agents in MDS and AML
2022 Webinar Recording
Learning Objectives

1. Review the mechanism of action and compare the pharmacokinetic profiles of oral hypomethylating agents to their parenteral counterparts.
2. Analyze results of key trials for decitabine/cedazuridine in myelodysplastic syndrome (MDS) and oral azacitidine in acute myeloid leukemia (AML).
3. Assess the place in therapy of oral hypomethylating agents for MDS and AML based on current approvals and guideline recommendations.
4. Design a patient-specific plan for dosing, administration, monitoring, and supportive care for each agent.